New Releases from NCBI BookshelfMirikizumab (Omvoh): Indication: For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment: Reimbursement Recommendation [Internet].​Mirikizumab (Omvoh): Indication: For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment: Reimbursement Recommendation [Internet].